title: Simultaneous treatment with statins and aspirin reduces the risk of prostate cancer detection and tumorigenic properties in prostate cancer cell lines.
abstract: Nowadays prostate cancer is the most common solid tumor in men from industrialized countries and the second leading cause of death. At the ages when PCa is usually diagnosed, mortality related to cardiovascular morbidity is high; therefore, men at risk for PCa frequently receive chronic lipid-lowering and antiplatelet treatment. The aim of this study was to analyze how chronic treatment with statins, aspirin, and their combination influenced the risk of PCa detection. The tumorigenic properties of these treatments were evaluated by proliferation, colony formation, invasion, and migration assays using different PCa cell lines, in order to assess how these treatments act at molecular level. The results showed that a combination of statins and aspirin enhances the effect of individual treatments and seems to reduce the risk of PCa detection (OR: 0.616 (95% CI: 0.467-0.812), P<0.001). However, if treatments are maintained, aspirin (OR: 1.835 (95% CI: 1.068-3.155), P=0.028) or the combination of both drugs (OR: 3.059 (95% CI: 1.894-4.939), P<0.001) represents an increased risk of HGPCa. As observed at clinical level, these beneficial effects in vitro are enhanced when both treatments are administered simultaneously, suggesting that chronic, concomitant treatment with statins and aspirin has a protective effect on PCa incidence.
authors: Research Unit in Biomedicine and Translational Oncology, Vall d'Hebron Research Institute and Hospital and Autonomous University of Barcelona, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
authors: M
authors: M
authors: Olivan
authors: Research Unit in Biomedicine and Translational Oncology, Vall d'Hebron Research Institute and Hospital and Autonomous University of Barcelona, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
authors: M
authors: M
authors: Rigau
authors: Research Unit in Biomedicine and Translational Oncology, Vall d'Hebron Research Institute and Hospital and Autonomous University of Barcelona, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
authors: E
authors: E
authors: Colás
authors: Research Unit in Biomedicine and Translational Oncology, Vall d'Hebron Research Institute and Hospital and Autonomous University of Barcelona, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
authors: M
authors: M
authors: Garcia
authors: Research Unit in Biomedicine and Translational Oncology, Vall d'Hebron Research Institute and Hospital and Autonomous University of Barcelona, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
authors: M
authors: M
authors: Montes
authors: Research Unit in Biomedicine and Translational Oncology, Vall d'Hebron Research Institute and Hospital and Autonomous University of Barcelona, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
authors: T
authors: T
authors: Sequeiros
authors: Department of Urology, Vall d'Hebron University Hospital and Autonomous University of Barcelona, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
authors: L
authors: L
authors: Regis
authors: Department of Urology, Vall d'Hebron University Hospital and Autonomous University of Barcelona, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
authors: A
authors: A
authors: Celma
authors: Department of Urology, Vall d'Hebron University Hospital and Autonomous University of Barcelona, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
authors: J
authors: J
authors: Planas
authors: Department of Urology, Vall d'Hebron University Hospital and Autonomous University of Barcelona, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
authors: J
authors: J
authors: Placer
authors: Research Unit in Biomedicine and Translational Oncology, Vall d'Hebron Research Institute and Hospital and Autonomous University of Barcelona, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain ; Departament de Ciències Bàsiques, Universitat Internacional de Catalunya, Josep Trueta s/n, Sant Cugat del Vallès, 08195 Barcelona, Spain ; Bellvitge Biomedical Research Institute (IDIBELL), Gran Via de l'Hospitalet 199, 08907 Barcelona, Spain.
authors: J
authors: J
authors: Reventós
authors: Research Unit in Biomedicine and Translational Oncology, Vall d'Hebron Research Institute and Hospital and Autonomous University of Barcelona, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain ; Department of Pathology, Vall d'Hebron University Hospital and Autonomous University of Barcelona, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
authors: I
authors: I
authors: de Torres
authors: Research Unit in Biomedicine and Translational Oncology, Vall d'Hebron Research Institute and Hospital and Autonomous University of Barcelona, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
authors: A
authors: A
authors: Doll
authors: Research Unit in Biomedicine and Translational Oncology, Vall d'Hebron Research Institute and Hospital and Autonomous University of Barcelona, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain ; Department of Urology, Vall d'Hebron University Hospital and Autonomous University of Barcelona, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
authors: J
authors: J
authors: Morote
mesh_terms: D000368:Aged; D001241:Aspirin / Q000494:pharmacology*; D001706:Biopsy; D016022:Case-Control Studies; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects*; D049109:Cell Proliferation / Q000187:drug effects*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D008297:Male; D011467:Prostate / Q000473:pathology; D011471:Prostatic Neoplasms / Q000453:epidemiology*; D012189:Retrospective Studies
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D001241:Aspirin
references: J Urol. 2000 Jul;164(1):101-5
references: 10840432
references: Int J Cancer. 2011 May 15;128(10):2444-52
references: 21128233
references: Epidemiol Rev. 2001;23(1):3-13
references: 11588851
references: Leukemia. 2002 Apr;16(4):508-19
references: 11960327
references: Cancer Causes Control. 2002 Jun;13(5):427-34
references: 12146847
references: Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):1108-11
references: 12376516
references: Int J Cancer. 2003 Sep 1;106(3):409-15
references: 12845682
references: Cancer Epidemiol Biomarkers Prev. 2004 Apr;13(4):649-53
references: 15066932
references: J Biol Chem. 1996 Jul 19;271(29):17453-62
references: 8663239
references: J Urol. 2011 Jul;186(1):86-90
references: 21571344
references: Nat Rev Urol. 2011 Aug;8(8):428-39
references: 21691304
references: Eur J Pharmacol. 2011 Dec 30;673(1-3):96-100
references: 22040920
references: Nat Rev Urol. 2012 Feb;9(2):102-10
references: 22270135
references: Cancer Epidemiol Biomarkers Prev. 2012 Apr;21(4):576-81
references: 22315364
references: Eur Urol. 2012 Jun;61(6):1079-92
references: 22424666
references: Lancet. 2012 Apr 28;379(9826):1591-601
references: 22440947
references: Ann Oncol. 2012 Jun;23(6):1403-15
references: 22517822
references: Br J Cancer. 2012 May 8;106(10):1689-96
references: 22531631
references: Cell Biol Toxicol. 2012 Oct;28(5):291-301
references: 22790656
references: CA Cancer J Clin. 2013 Jan;63(1):11-30
references: 23335087
references: Urol Clin North Am. 1996 Nov;23(4):521-30
references: 8948407
references: Cancer Epidemiol Biomarkers Prev. 1998 Oct;7(10):869-73
references: 9796631
references: Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):390-6
references: 15734963
references: Oncol Rep. 2005 Apr;13(4):559-83
references: 15756426
references: J Natl Cancer Inst. 2005 Jul 6;97(13):975-80
references: 15998950
references: J Urol. 2005 Oct;174(4 Pt 1):1256-60; discussion 1260-1; author reply 1261
references: 16145388
references: Nat Rev Drug Discov. 2005 Dec;4(12):977-87
references: 16341063
references: Eur J Cancer Prev. 2006 Feb;15(1):43-5
references: 16374228
references: Curr Cancer Drug Targets. 2005 Dec;5(8):579-94
references: 16375664
references: Cancer J. 2006 Mar-Apr;12(2):130-5
references: 16630404
references: JAMA. 2006 Oct 4;296(13):1633-44
references: 16968831
references: Am J Epidemiol. 2006 Nov 15;164(10):984-9
references: 16931544
references: Am J Epidemiol. 2007 Aug 1;166(3):348-54
references: 17504779
references: Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):88-94
references: 18199714
references: Int J Cancer. 2008 Aug 15;123(4):899-904
references: 18491405
references: Nat Clin Pract Urol. 2008 Jul;5(7):376-87
references: 18542103
references: Neoplasia. 2008 Aug;10(8):797-803
references: 18670640
references: Ann Pharmacother. 2008 Sep;42(9):1208-15
references: 18648016
references: Curr Cancer Drug Targets. 2008 Dec;8(8):753-64
references: 19075598
references: N Engl J Med. 2009 Mar 26;360(13):1310-9
references: 19297565
references: N Engl J Med. 2009 Mar 26;360(13):1320-8
references: 19297566
references: Int J Oncol. 2009 Jun;34(6):1717-26
references: 19424590
references: Prostate. 2009 Jun 15;69(9):1017-23
references: 19301305
references: Pharmacotherapy. 2010 Feb;30(2):177-94
references: 20099992
references: Prostate. 2010 Jun 1;70(8):883-8
references: 20135645
references: Cancer Res. 2010 Aug 1;70(15):6359-67
references: 20631072
references: Int J Cancer. 2010 Oct 1;127(7):1650-9
references: 20073066
references: Int J Cancer. 2010 Oct 1;127(7):1680-91
references: 20091856
references: Minn Med. 2010 Aug;93(8):39-44
references: 20862878
references: Cancer Epidemiol Biomarkers Prev. 2010 Dec;19(12):3185-8
references: 20935064
references: J Clin Invest. 2011 Jan;121(1):226-37
references: 21135504
references: Circulation. 2000 Oct 24;102(17):2022-3
references: 11044413